Loss of HLA class I expression in prostate cancer: implications for immunotherapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/99427
Title:
Loss of HLA class I expression in prostate cancer: implications for immunotherapy.
Authors:
Blades, R A; Keating, P J; McWilliam, L J; George, Nicholas J; Stern, Peter L
Abstract:
OBJECTIVES: There is currently no reliable predictor of the metastatic potential of apparently localized prostate cancer in an individual patient or satisfactory treatment for patients with advanced disease. One of the factors that may influence tumor progression is the cellular arm of the immune response, and central to this is the human leukocyte antigen (HLA) system, which acts to restrict T-cell recognition of potential tumor antigens. It has been reported in some cancers that down regulation of HLA class I expression by the tumor cells is associated with poor prognosis. In this report, HLA class I and II expression have been investigated in both benign and malignant prostate disease, first to define the extent of altered HLA expression and second to assess whether HLA expression may be related to disease progression. METHODS: HLA expression was assessed by immunohistochemistry utilizing a set of monoclonal antibodies that recognize both monomorphic determinants and the commoner HLA class I allelic products. RESULTS: In contrast to the normal HLA class I expression of the benign tissue, complete loss of HLA class I expression occurred in 34% of primary prostate cancers and 80% of lymph node metastases. When individual allelic expression was assessed, the minimum estimate of down regulation was 85% in the primary prostate cancers and 100% of the metastases. CONCLUSIONS: This investigation has demonstrated a higher rate of HLA class I loss than has been reported in other tumors and would suggest that the immune system may have an important role in the progression of prostate cancer, as well as having implications for the design and success of immunotherapy regimens in advanced disease.
Affiliation:
Department of Urology, University Hospital of South Manchester, United Kingdom.
Citation:
Loss of HLA class I expression in prostate cancer: implications for immunotherapy. 1995, 46 (5):681-6 Urology
Journal:
Urology
Issue Date:
Nov-1995
URI:
http://hdl.handle.net/10541/99427
DOI:
10.1016/S0090-4295(99)80301-X
PubMed ID:
7495121
Type:
Article
Language:
en
ISSN:
0090-4295
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorBlades, R Aen
dc.contributor.authorKeating, P Jen
dc.contributor.authorMcWilliam, L Jen
dc.contributor.authorGeorge, Nicholas Jen
dc.contributor.authorStern, Peter Len
dc.date.accessioned2010-05-20T15:13:23Z-
dc.date.available2010-05-20T15:13:23Z-
dc.date.issued1995-11-
dc.identifier.citationLoss of HLA class I expression in prostate cancer: implications for immunotherapy. 1995, 46 (5):681-6 Urologyen
dc.identifier.issn0090-4295-
dc.identifier.pmid7495121-
dc.identifier.doi10.1016/S0090-4295(99)80301-X-
dc.identifier.urihttp://hdl.handle.net/10541/99427-
dc.description.abstractOBJECTIVES: There is currently no reliable predictor of the metastatic potential of apparently localized prostate cancer in an individual patient or satisfactory treatment for patients with advanced disease. One of the factors that may influence tumor progression is the cellular arm of the immune response, and central to this is the human leukocyte antigen (HLA) system, which acts to restrict T-cell recognition of potential tumor antigens. It has been reported in some cancers that down regulation of HLA class I expression by the tumor cells is associated with poor prognosis. In this report, HLA class I and II expression have been investigated in both benign and malignant prostate disease, first to define the extent of altered HLA expression and second to assess whether HLA expression may be related to disease progression. METHODS: HLA expression was assessed by immunohistochemistry utilizing a set of monoclonal antibodies that recognize both monomorphic determinants and the commoner HLA class I allelic products. RESULTS: In contrast to the normal HLA class I expression of the benign tissue, complete loss of HLA class I expression occurred in 34% of primary prostate cancers and 80% of lymph node metastases. When individual allelic expression was assessed, the minimum estimate of down regulation was 85% in the primary prostate cancers and 100% of the metastases. CONCLUSIONS: This investigation has demonstrated a higher rate of HLA class I loss than has been reported in other tumors and would suggest that the immune system may have an important role in the progression of prostate cancer, as well as having implications for the design and success of immunotherapy regimens in advanced disease.en
dc.language.isoenen
dc.subjectProstatic Canceren
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshGene Expression Regulation, Neoplastic-
dc.subject.meshGenes, MHC Class I-
dc.subject.meshHumans-
dc.subject.meshImmunotherapy-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshProstatic Neoplasms-
dc.titleLoss of HLA class I expression in prostate cancer: implications for immunotherapy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Urology, University Hospital of South Manchester, United Kingdom.en
dc.identifier.journalUrologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.